Elekta (OTCMKTS:EKTAY) Sees Unusually-High Trading Volume – What’s Next?

Shares of Elekta AB (OTCMKTS:EKTAY) saw unusually-strong trading volume on Thursday. 7,211 shares traded hands during mid-day trading, an increase of 160% from the average daily volume of 2,778 shares. The stock last traded at $6.16 and had previously closed at $6.00.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of Elekta from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Hold rating. According to MarketBeat.com, Elekta has an average rating of “Hold”.

Elekta Price Performance

The firm has a market cap of $2.27 billion, a P/E ratio of -51.33 and a beta of 1.01. The company has a current ratio of 0.86, a quick ratio of 0.62 and a debt-to-equity ratio of 0.45. The business has a 50-day moving average of $5.43 and a two-hundred day moving average of $5.69.

Elekta (OTCMKTS:EKTAY) last posted its earnings results on Thursday, August 27th. The company reported $0.07 EPS for the quarter. Elekta had a positive return on equity of 13.47% and a negative net margin of 2.38%. The firm had revenue of $372.30 million during the quarter. On average, sell-side analysts anticipate that Elekta AB will post 0.43 earnings per share for the current fiscal year.

Elekta Company Profile

Elekta AB is a Sweden-based medical technology company that develops and supplies systems and software for radiation therapy, radiosurgery and related cancer-care applications. Its solutions are designed to help hospitals and clinics treat tumors while supporting more precise, personalized and less invasive care.

The company’s portfolio includes linear accelerators, stereotactic radiosurgery systems, magnetic resonance-guided radiation therapy technology and brachytherapy products. Elekta also provides oncology information systems and workflow software, including platforms used for treatment planning, patient management and clinical data coordination.

Founded in 1972 by neurosurgeon and inventor Lars Leksell, Elekta initially focused on radiosurgery and later expanded into broader radiation oncology.